Eloxx Pharmaceuticals
Biotechnology, 480 Arsenal Way Ste 130, Watertown, Massachusetts, 02472, United States, 11-50 Employees
Phone Number: 78********
Who is ELOXX PHARMACEUTICALS
Eloxx Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company developing novel RNA-modulating drug candidates that are designed to treat rare and ultra-rare premature stop cod...
Read More
-
Headquarters: 480 Arsenal Way Ste 130, Watertown, Massachusetts, 02472, United States
-
Date Founded: 2013
-
Employees: 11-50
-
Revenue: $1 Million to $5 Million
-
Active Tech Stack: See technologies
Industry: Biotechnology
SIC Code: 2836
|
NAICS Code: 325414 |
Show More
Does something look wrong? Fix it. | View contact records from ELOXX PHARMACEUTICALS
Eloxx Pharmaceuticals Org Chart and Mapping
Email
Phone
Douglas McMillin
Director, Business Development & Alliance Management / Interim Program Head - Ocular Program
Sign in to CIENCE GO Data to uncover contact details
Free credits every month
Frequently Asked Questions Regarding Eloxx Pharmaceuticals
Answer: Eloxx Pharmaceuticals's headquarters are located at 480 Arsenal Way Ste 130, Watertown, Massachusetts, 02472, United States
Answer: Eloxx Pharmaceuticals's phone number is 78********
Answer: Eloxx Pharmaceuticals's official website is https://eloxxpharma.com
Answer: Eloxx Pharmaceuticals's revenue is $1 Million to $5 Million
Answer: Eloxx Pharmaceuticals's SIC: 2836
Answer: Eloxx Pharmaceuticals's NAICS: 325414
Answer: Eloxx Pharmaceuticals has 11-50 employees
Answer: Eloxx Pharmaceuticals is in Biotechnology
Answer: Eloxx Pharmaceuticals contact info: Phone number: 78******** Website: https://eloxxpharma.com
Answer: Eloxx Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company developing novel RNA-modulating drug candidates that are designed to treat rare and ultra-rare premature stop codon diseases. Premature stop codons are point mutations that disrupt protein synthesis from messenger RNA. As a consequence, patients with premature stop codon diseases have reduced or eliminated protein production from the mutation bearing allele accounting for some of the most severe phenotypes in these genetic diseases. These premature stop codons have been identified in over 1,800 rare and ultra-rare diseases. Read-through therapeutic development is focused on extending mRNA half-life and increasing protein synthesis by enabling the cytoplasmic ribosome to read through premature stop codons to produce full-length proteins. Eloxxs lead product candidate, ELX-02, is a small molecule drug candidate designed to restore production of full-length functional proteins. ELX-02 is in the early stages of clinical development focusing on cystic fibrosis and cystinosis. ELX-02 is an investigational drug that has not been approved by any global regulatory body. Eloxx is headquartered in Waltham, MA, with R&D operations in Rehovot, Israel.
Premium Sales Data for Prospecting
-
Sales data across over 200M records
-
Up-to-date records (less decayed data)
-
Accurate Email Lists (real-world tested)
-
Powerful search engine and intuitive interface
Get Full Access
Sign in to CIENCE GO Data to uncover contact details
Free credits every month